169 related articles for article (PubMed ID: 33443026)
1. Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.
Sajiki Y; Konnai S; Cai Z; Takada K; Okagawa T; Maekawa N; Fujisawa S; Kato Y; Suzuki Y; Murata S; Ohashi K
Immunohorizons; 2020 Dec; 4(12):837-850. PubMed ID: 33443026
[TBL] [Abstract][Full Text] [Related]
2. Combination of EP
Wang Y; Cui L; Georgiev P; Singh L; Zheng Y; Yu Y; Grein J; Zhang C; Muise ES; Sloman DL; Ferguson H; Yu H; Pierre CS; Dakle PJ; Pucci V; Baker J; Loboda A; Linn D; Brynczka C; Wilson D; Haines BB; Long B; Wnek R; Sadekova S; Rosenzweig M; Haidle A; Han Y; Ranganath SH
Oncoimmunology; 2021 Mar; 10(1):1896643. PubMed ID: 33796403
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E
Sajiki Y; Konnai S; Okagawa T; Nishimori A; Maekawa N; Goto S; Ikebuchi R; Nagata R; Kawaji S; Kagawa Y; Yamada S; Kato Y; Nakajima C; Suzuki Y; Murata S; Mori Y; Ohashi K
Infect Immun; 2018 May; 86(5):. PubMed ID: 29483289
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
6. PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Ganbaatar O; Konnai S; Okagawa T; Nojima Y; Maekawa N; Minato E; Kobayashi A; Ando R; Sasaki N; Miyakoshi D; Ichii O; Kato Y; Suzuki Y; Murata S; Ohashi K
PLoS One; 2020; 15(11):e0234218. PubMed ID: 33216754
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
De Luca R; Neri D
Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E
Sajiki Y; Konnai S; Okagawa T; Nishimori A; Maekawa N; Goto S; Watari K; Minato E; Kobayashi A; Kohara J; Yamada S; Kaneko MK; Kato Y; Takahashi H; Terasaki N; Takeda A; Yamamoto K; Toda M; Suzuki Y; Murata S; Ohashi K
J Immunol; 2019 Sep; 203(5):1313-1324. PubMed ID: 31366713
[TBL] [Abstract][Full Text] [Related]
9. Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Chu TH; Vo MC; Park HS; Lakshmi TJ; Jung SH; Kim HJ; Lee JJ
Cancer Immunol Immunother; 2021 Jan; 70(1):31-45. PubMed ID: 32623477
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.
Bonfill-Teixidor E; Otxoa-de-Amezaga A; Font-Nieves M; Sans-Fons MG; Planas AM
J Neuroinflammation; 2017 Jan; 14(1):3. PubMed ID: 28086956
[TBL] [Abstract][Full Text] [Related]
11. Tick saliva-induced programmed death-1 and PD-ligand 1 and its related host immunosuppression.
Sajiki Y; Konnai S; Ikenaka Y; Gulay KCM; Kobayashi A; Parizi LF; João BC; Watari K; Fujisawa S; Okagawa T; Maekawa N; Logullo C; da Silva Vaz I; Murata S; Ohashi K
Sci Rep; 2021 Jan; 11(1):1063. PubMed ID: 33441793
[TBL] [Abstract][Full Text] [Related]
12. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
13. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
14. Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Kearl TJ; Jing W; Gershan JA; Johnson BD
J Immunol; 2013 Jun; 190(11):5620-8. PubMed ID: 23616570
[TBL] [Abstract][Full Text] [Related]
15. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
18. Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies.
Zhang W; Lim SM; Hwang J; Ramalingam S; Kim M; Jin JO
Cancer Immunol Immunother; 2021 Mar; 70(3):689-700. PubMed ID: 32902663
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E₂ down-regulates the expression of CD25 on bovine T cells, and this effect is mediated through the EP4 receptor.
Maślanka T; Spodniewska A; Barski D; Jasiecka A; Zuśka-Prot M; Ziółkowski H; Markiewicz W; Jaroszewski JJ
Vet Immunol Immunopathol; 2014 Aug; 160(3-4):192-200. PubMed ID: 25001909
[TBL] [Abstract][Full Text] [Related]
20. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
